359 related articles for article (PubMed ID: 23391115)
1. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
3. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
4. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Kulke MH
J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
[No Abstract] [Full Text] [Related]
5. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
8. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Benavent M; de Miguel MJ; Garcia-Carbonero R
Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
[TBL] [Abstract][Full Text] [Related]
9. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
12. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Crippa S; Partelli S; Boninsegna L; Falconi M
Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
[No Abstract] [Full Text] [Related]
13. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
14. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
15. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
16. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
17. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
18. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
19. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
20. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]